RxDoctor Payments Data

Joel Clarfield, MD

Internal Medicine · Mission Hills, CANPI 1700941788

Payments from drug & device makers

$1,381in general payments, 2019–2025

Across 18 payments — averaging $76.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$377
  • Johnson & Johnson$242
  • Pfizer$144
  • Amgen$125
  • Boehringer Ingelheim$125
  • Teva Pharmaceuticals USA, Inc.$122
  • plus $245 from 3 others

What the payments were for

  • Food & beverage$1,381100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,381 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$175,342
Medicare patients
146
Services billed
11,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$84,625
JardianceEmpagliflozin89$69,580
OzempicSemaglutide59$55,929
FarxigaDapagliflozin Propanediol47$29,745
XareltoRivaroxaban33$23,805
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$22,788
JanuviaSitagliptin Phosphate19$22,495
TrulicityDulaglutide14$13,546
TradjentaLinagliptin16$11,877
MyrbetriqMirabegron18$8,094
EntrestoSacubitril/Valsartan11$7,613
Metformin Er GastricMetformin Hcl26$6,800
VascepaIcosapent Ethyl36$6,714
Atorvastatin Calcium555$6,242
Mirtazapine172$6,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$144$87,483155 claims
Boehringer IngelheimJardiance, Tradjenta$125$81,457105 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$377$33,65365 claims
Johnson & JohnsonXarelto$242$23,80533 claims
GSKTrelegy Ellipta$119$22,78826 claims
NovartisEntresto$30$7,61311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →